Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;51(3):864-870.
doi: 10.1007/s00259-023-06490-z. Epub 2023 Nov 8.

The prognostic role of next-generation imaging-driven upstaging in newly diagnosed prostate cancer patients

Matteo Bauckneht  1   2 , Enrico Checcucci  3 , Edoardo Cisero  4 , Alessio Rizzo  5 , Manuela Racca  5 , Sabrina De Cillis  4 , Daniele Amparore  4 , Stefano De Luca  4 , Cristian Fiori  4 , Pasquale Rescigno  3   6 , Francesco Porpiglia  4
Affiliations

The prognostic role of next-generation imaging-driven upstaging in newly diagnosed prostate cancer patients

Matteo Bauckneht et al. Eur J Nucl Med Mol Imaging. 2024 Feb.

Abstract

Purpose: Phase III evidence showed that next-generation imaging (NGI), such as prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT), provides higher diagnostic accuracy than bone scan and contrast-enhanced computed tomography (conventional imaging, CI) in the primary staging of intermediate-to-high-risk prostate cancer (PCa) patients. However, due to the lack of outcome data, the introduction of NGI in routine clinical practice is still debated. Analysing the oncological outcome of patients upstaged by NGI (though managed according to CI) might shed light on this issue, supporting the design of randomised trials comparing the effects of treatments delivered based on NGI vs. CI.

Methods: We prospectively enrolled a cohort of 100 biopsy-proven intermediate-to-high-risk PCa patients staged with CI and PSMA PET/CT (though managed according to the CI stage), to assess the frequency of the stage migration phenomenon. Stage migration was then assessed as biochemical recurrence-free survival (bRFS) predictor.

Results: Three patients were lost at follow-up after imaging. PSMA PET/CT upstaged 26.8% of patients compared to CI, while it downstaged 6.1% of patients. Notably, 50% of patients excluded from surgery due to the presence of bone metastases at CI would have been treated with radical-intent approaches if PSMA PET/CT had guided the treatment choice. After a median follow-up of 6 months of surgically treated patients, 22/83 (26.5%) had biochemical recurrence (BCR). PSMA PET/CT-driven upstaging determined a significant risk increase for BCR (HR:3.41, 95%CI:1.21-9.56, p = 0.019). Including stage migration in a univariable and multivariable model identified PSMA PET/CT-upstaging as an independent predictor of bRFS.

Conclusions: In conclusion, implementing NGI for staging purposes improves the prediction of bRFS. Although phase III evidence is still needed, this advancement suggests that NGI may better identify patients who would benefit from local treatments than those who may achieve better oncological outcomes through systemic treatment.

Keywords: Biochemical recurrence; Conventional imaging; PSMA PET; Primary staging; Prostate cancer; Stage migration.

PubMed Disclaimer

References

    1. Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–16. - PubMed
    1. Varatharajan A, Olivier T, Prasad V. Prostate-specific membrane antigen positron emission tomography in the staging of newly diagnosed prostate cancer: is more sensitivity always better? Eur Urol. 2023;83:481–3. - PubMed
    1. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978–94–92671–19–6.
    1. Fanti S, Briganti A, Emmett L, Fizazi K, Gillessen S, Goffin K, et al. EAU-EANM consensus statements on the role of prostate-specific membrane antigen positron emission tomography/computed tomography in patients with prostate cancer and with respect to [177Lu]Lu-PSMA radioligand therapy. Eur Urol Oncol. 2022;5:530–6. - PubMed
    1. Van den Wyngaert T, Strobel K, Kampen WU, Kuwert T, van der Bruggen W, Mohan HK, et al. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging. 2016;43:1723–38. - PubMed - PMC

Substances

LinkOut - more resources